bevacizumab | Cancer Search

Details 99 Trials 20 Therapies

A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.

codes

FDA: 2S9ZZM9Q9V

NCIt: C2039

synonym

Avastin

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

217 sites for NCT03737643

Fallopian Tube Carcinoma, +5 more conditions

bevacizumab, +5 more drugs

chemotherapy, +2 more types

Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

200 sites for NCT03847428

Hepatocellular Carcinoma

bevacizumab, +2 more drugs

immunotherapy, +1 more type

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)

14 sites for NCT05116189

Fallopian Tube Carcinoma, +2 more conditions

bevacizumab, +3 more drugs

chemotherapy, +2 more types

Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)

106 sites for NCT04456699

Colorectal Adenocarcinoma

bevacizumab, +1 more drug

targeted therapy

Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

639 sites for NCT04094688

Colorectal Adenocarcinoma

bevacizumab, +3 more drugs

chemotherapy, +2 more types

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

343 sites for NCT04181060